• Explore /
  • Poster
  • / Incidence and risk factors for central nervous system (CNS) metastasis (met) in patients (pts) with stage III melanoma treated with adjuvant (ADJ) anti-PD1 immunotherapy (IMT).

Incidence and risk factors for central nervous system (CNS) metastasis (met) in patients (pts) with stage III melanoma treated with adjuvant (ADJ) anti-PD1 immunotherapy (IMT).

Abstract Poster

Authors

Michael Davies

Michael A. Davies

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Michael A. Davies , Julie Simon , Alexander M. Menzies , Denai R. Milton , James S. Wilmott , Debora Alejandra Ledesma , Elizabeth M. Burton , Sherise D. Ferguson , Hussein A. Tawbi , Jeffrey E. Gershenwald , Carlos A. Torres-Cabala , Isabella Claudia Glitza , Alexander J. Lazar , Robyn P.M. Saw , Andrew John Spillane , Matteo S. Carlino , Richard A Scolyer , Georgina V. Long

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Local-Regional Disease

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 9581)

DOI

10.1200/JCO.2024.42.16_suppl.9581

Abstract #

9581

Poster Bd #

365

Abstract Disclosures

Similar Posters

First Author: Inderjit Mehmi

First Author: Zeynep Eroglu

First Author: Vincent T Ma

Poster

2021 ASCO Annual Meeting

Efficacy of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy.

Efficacy of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy.

First Author: Prachi Bhave